Desmoid Tumor clinical trials at UCSF

4 in progress, 2 open to eligible people

Desmoid tumors are non-cancerous growths that can occur in muscles and other tissues. UCSF is gathering health data from young cancer patients in one study. Another trial is looking at the safety and effects of a drug called tegavivint on desmoid tumors.

Showing trials for

  • Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

    open to eligible people ages 12 months to 30 years

    This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.

    San Francisco, California and other locations

  • Project: Every Child for Younger Patients With Cancer

    open to eligible people ages up to 25 years

    This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

    Oakland, California and other locations

  • New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

    Sorry, in progress, not accepting new patients

    This phase II trial studies the side effects and how well nirogacestat works in treating patients less than 18 years of age with desmoid tumors that has grown after at least one form of treatment by mouth or in the vein that cannot be removed by surgery. Nirogacestat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

    Oakland, California and other locations

  • Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

    Sorry, in progress, not accepting new patients

    This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). In the double-blind phase, half of the participants will receive nirogacestat while the other half will receive placebo. Once participants are eligible to roll into the open-label phase, they will receive nirogacestat.

    San Francisco, California and other locations

Our lead scientists for Desmoid Tumor research studies include .

Last updated: